This year the IPO pipeline was expected to be robust again, on the expectation of a business environment with reduced regulations and lower tax rates on the horizon.

Instead, the IPO pipeline seems to have largely come to a halt as soon as it began to look like large deals (tech, and biotech, in particular) were due to resume.

In…